On April 26, 2023 Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, reported that the results of the Phase I/II TORCH-2 study will be presented as a poster discussion during the American Society for Clinical Oncology Annual Meeting (ASCO 2023), taking place from June 2nd to 6th at the McCormick Place Convention Center in Chicago, IL (Press release, Antengene, APR 26, 2023, View Source [SID1234630560]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The TORCH-2 study is an open-label dose escalation and expansion study to evaluate ATG-008, an mTORC1/2 inhibitor, in combination with the anti-PD-L1 antibody, toripalimab, in patients with advanced solid tumors.
"We believe that combining ATG-008 with an immune checkpoint inhibitor could lead to more effective and durable control of tumors, because the mTOR signaling pathway plays multiple roles in immune cell biology. We look forward to sharing the results of the TORCH-2 study with the oncology community at ASCO (Free ASCO Whitepaper) 2023." said Dr. Amily Zhang, Antengene’s Chief Medical Officer.
Details of the poster to be presented:
Title: A phase I/II study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors
Abstract: 2526
Session: Developmental Therapeutics – Immunotherapy
Poster Session Display Date and Time: 8:00 AM – 11:00 AM, June 3, 2023 (Central Time) / 9:00 PM, June 3 – 12:00 AM, June 4, 2023 (Beijing Time)
Poster Board Number: 368
Poster Discussion Session Date and Time: 3:00 PM – 4:30 PM, June 3, 2023 (Central Time) / 4:00 AM – 5:30 AM, June 4, 2023 (Beijing Time)